A Phase I Study of BGT226, Administered Orally in Adult Patients With Advanced Solid Tumor in Japan.
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2016
At a glance
- Drugs BGT 226 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors Novartis Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 05 May 2010 Actual number of patients (57) added as reported by ClinicalTrials.gov record.
- 05 May 2010 Actual end date (1 MAr 2010) added as reported by ClinicalTrials.gov record.